EGFR and adenocarcinoma: Patients with advanced stage adenocarcinoma were classified based on EGFR mutation status (n = 517) and CEAPd information (n = 288), and the demographic profiles of these patients, including age, gender, clinical stage, smoking, EGFR status, and CEAIn and CEAPd levels, are listed in Table 1.